

Elsevier Editorial System(tm) for Differentiation
Manuscript Draft

Manuscript Number:

Title: The GM-CSF receptor utilizes β -catenin and Tcf4 to specify macrophage lineage differentiation

Article Type: Research Paper

Keywords: Myeloid, transcription-factor, β -catenin, Tcf4, signal-transduction

Corresponding Author: A/Prof Richard J D'Andrea, PhD

Corresponding Author's Institution: Division of Haematology, Centre for Cancer Biology, SA Pathology, Frome Rd, Adelaide, SA, 5000, Australia

First Author: Anna Louise Brown, Ph.D

Order of Authors: Anna Louise Brown, Ph.D; Diana G Salerno, BSc (Hons); Teresa Sadras, BSc (Hons); Chung H Kok, PhD; Christopher R Wilkinson, PhD; Saumya E Samaraweera, BSc (Hons); Timothy J Sadlon, PhD; Michelle Perugini, PhD; Ian D Lewis, MBBS, PhD; Thomas J Gonda, PhD; Richard J D'Andrea, PhD

Abstract: Granulocyte-macrophage colony stimulating factor (GM-CSF) promotes the growth, survival, differentiation and activation of normal myeloid cells and is essential for fully functional macrophage differentiation in vivo. To better understand the mechanisms by which growth factors control the balance between proliferation and self-renewal versus growth-suppression and differentiation we have used the bi-potent FDB1 myeloid cell line, which proliferates in IL-3 and differentiates to granulocytes and macrophages in response to GM-CSF. This provides a manipulable model in which to dissect the switch between growth and differentiation. We show that, in the context of signaling from an activating mutant of the GM-CSF receptor β subunit, a single intracellular tyrosine residue (Y577) mediates the granulocyte fate decision. Loss of granulocyte differentiation in a Y577F second-site mutant is accompanied by enhanced macrophage differentiation, accumulation of β -catenin together with activation of Tcf4 and other Wnt target genes. These include the known macrophage lineage inducer, Egr1. Further, we show that forced expression of Tcf4 or a stabilised β -catenin mutant is sufficient to promote macrophage differentiation in response to GM-CSF, and that GM-CSF can regulate β -catenin stability. This study therefore identifies a novel pathway through which growth factor receptor signalling can interact with transcriptional regulators to influence lineage choice during myeloid differentiation.

Suggested Reviewers: Christian Buske
christian.buske@uni-ulm.de
relevant expertise

Wallace Langdon
wally.langdon@uwa.edu.au
relevant expertise

Opposed Reviewers:

Dr Richard D'Andrea, PhD

Chief Medical Scientist,
Division of Haematology
Centre for Cancer Biology, SA Pathology
and
The Queen Elizabeth Hospital
Associate Professor
Disciplines of Paediatrics and Genetics
University of Adelaide

Phone: 61 8 8222 3636
Email: Richard.dandrea@imvs.sa.gov.au

May 27, 2011

The Editor

Differentiation

Dear Dr Stewart

We are submitting for your consideration, a manuscript entitled 'The GM-CSF receptor utilizes β -catenin and Tcf4 to specify macrophage lineage differentiation'.

In this study we describe a novel function of the GM-CSF receptor to regulate members of the Wnt/ β -catenin pathway and in-turn specify the level of macrophage differentiation in the context of a bi-potential granulocyte-macrophage progenitor. Specifically, we provide evidence that β -catenin and Tcf4 are central in promoting macrophage differentiation and activity of these is regulated through a specific tyrosine in the GM-CSF receptor.

We believe that as these findings suggest a new mechanism that may regulate differentiation within the myeloid compartment they are of significant interest to the readership of *Differentiation*.

All authors concur with the submission of this manuscript. This material contained in this manuscript is original research and has not been previously reported and is not under consideration for publication elsewhere.

Conflict of interest statement: The authors declare no competing financial interests.

Thank you for your consideration. We look forward to your response.

Sincerely,



A/Prof. Richard D'Andrea
Corresponding Author

Original Article

Title: The GM-CSF receptor utilizes β -catenin and Tcf4 to specify macrophage lineage differentiation.

Authors: Anna L. Brown^{a,b}, Diana G. Salerno^a, Teresa Sadras^{a,b}, Chung H. Kok^{a,b}, Christopher R. Wilkinson^{c,d}, Saumya E. Samaraweera^b, Timothy J. Sadlon^c, Michelle Perugini^{a,b}, Ian D. Lewis^{a,e}, Thomas J. Gonda^f and Richard J. D'Andrea^{a,b,e,g,*}.

^aDivision of Haematology, Centre for Cancer Biology, SA Pathology, Frome Rd, Adelaide, SA, 5000, Australia.

^bSchool of Molecular and Biomedical Science, University of Adelaide, SA, 5005, Australia.

^cWomen's and Children's Health Research Institute, 72 King William Rd, North Adelaide, 5006, Australia.

^dSchool of Applied Mathematics, University of Adelaide, SA, 5005, Australia.

^eThe Centre for Stem Cell Research, Robinson Institute, University of Adelaide.

^fUniversity of Queensland Diamantina Institute, Princess Alexandra Hospital, Ipswich Road, Buranda, Queensland 4102, Australia.

^gDepartment of Haematology and Oncology, The Queen Elizabeth Hospital, Adelaide, Australia.

Summary sentence: Signaling from the GM-CSF receptor modulates β -catenin and Tcf4, to influence macrophage lineage commitment.

Running title: GM-CSF and β -catenin in macrophage differentiation

*Corresponding Author

A/Prof Richard D'Andrea

Division of Haematology

Centre for Cancer Biology, SA Pathology

Frome Road, Adelaide

South Australia, 5000, Australia

Phone: 61-8-82223636

Fax: 61-8-82223737

Email: Richard.dandrea@health.sa.gov.au

Key Words Myeloid, transcription-factor, β -catenin, Tcf4, signal-transduction

Abstract

1
2 Granulocyte-macrophage colony stimulating factor (GM-CSF) promotes the growth, survival,
3
4 differentiation and activation of normal myeloid cells and is essential for fully functional
5
6 macrophage differentiation *in vivo*. To better understand the mechanisms by which growth
7
8 factors control the balance between proliferation and self-renewal versus growth-suppression
9
10 and differentiation we have used the bi-potent FDB1 myeloid cell line, which proliferates in
11
12 IL-3 and differentiates to granulocytes and macrophages in response to GM-CSF. This
13
14 provides a manipulable model in which to dissect the switch between growth and
15
16 differentiation. We show that, in the context of signaling from an activating mutant of the
17
18 GM-CSF receptor β subunit, a single intracellular tyrosine residue (Y577) mediates the
19
20 granulocyte fate decision. Loss of granulocyte differentiation in a Y577F second-site mutant
21
22 is accompanied by enhanced macrophage differentiation, accumulation of β -catenin together
23
24 with activation of *Tcf4* and other Wnt target genes. These include the known macrophage
25
26 lineage inducer, *Egr1*. Further, we show that forced expression of Tcf4 or a stabilised β -
27
28 catenin mutant is sufficient to promote macrophage differentiation in response to GM-CSF,
29
30 and that GM-CSF can regulate β -catenin stability. This study therefore identifies a novel
31
32 pathway through which growth factor receptor signalling can interact with transcriptional
33
34 regulators to influence lineage choice during myeloid differentiation.
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57

58 *Abbreviations:* GM, granulocyte macrophage; GMR, GM-CSF receptor; DC, dendritic cell; IPA, ingenuity
59 pathway analysis; BIO, (2'Z,3'E)-6-Bromoindirubin-3'-oxime
60
61
62
63
64
65

Introduction

In this study we examine the process of granulocyte and macrophage lineage specification mediated via Granulocyte-macrophage colony stimulating factor (GM-CSF) signaling. GM-CSF is a hematopoietic growth factor that can provide both permissive and instructive signals for myeloid differentiation (Kondo et al., 2000) and has been shown to play a critical role in DC function (Conti and Gessani, 2008). *In vivo* administration of GM-CSF promotes increased production of granulocytes and macrophages demonstrating its key role *in vivo* in driving coordinated proliferation and differentiation of GM progenitors (Metcalf et al., 1987). In particular, under steady-state conditions, GM-CSF signaling has a non-redundant role in mature macrophage production, with loss of GM-CSF signaling in mouse and humans leading to pulmonary alveolar proteinosis due to defects in alveolar macrophages (Dranoff et al., 1994; Suzuki et al., 2008; Martinez-Moczygemba et al., 2008; Nishinakamura et al., 1995). Null animals also display compromised antigen-specific and LPS-induced T-cell responses and IFN γ production, which may be DC-mediated, have defects in macrophage function and are susceptible to various infectious agents (Enzler et al., 2003; Paine et al., 2000). The high affinity receptors for human GM-CSF (GMR), IL-3 (IL3R) and IL-5 (IL5R) are each comprised of unique ligand-specific α subunits (GMR α , IL3R α or IL5R α) and a shared β subunit (h β_c) which are all members of the cytokine receptor superfamily (for review see (Miyajima et al., 1993; Lopez et al., 2010). Each ligand binds to its specific α -subunit to form a low affinity intermediate which we, and others have shown to form a signaling complex that is likely to include a dimer of h β_c and, at least in the case of the GMR, has been recently shown to form a higher order dodecameric complex for the full range of ligand induced signaling (McClure et al., 2001; McClure et al., 2003; Hansen et al.,

1 2008). $h\beta_c$ is the primary signaling subunit and mutation can result in constitutive activation
2
3 with a range of mutants now described that display alternative phenotypes and signaling
4
5 profiles (D'Andrea et al., 1998; McCormack and Gonda, 1999; Jenkins et al., 1995; Brown et
6
7 al., 2004; Perugini et al.; 2010).
8
9

10 Mutational studies of the GMR have identified intracellular regions and key residues of the
11
12 $GMR\alpha$ and $h\beta_c$ that are responsible for the signaling required for myeloid differentiation
13
14 versus growth. In particular, the region of $h\beta_c$ containing Tyr577 is important for mediating
15
16 GM-CSF induced myeloid differentiation of M1 and WEHI-3B D+ cells, where macrophage
17
18 differentiation is induced in response to ligand, however particular residues in this region
19
20 were not linked to the response (Smith et al., 1997). Studies with activated mutants of $h\beta_c$,
21
22 showing reduced signaling complexity compared to the wild type receptor, have facilitated
23
24 dissection of signaling networks downstream of the GM-CSF receptor, and allowed particular
25
26 signaling events to be assigned to cellular outcomes (Brown et al., 2004; Perugini et al.,
27
28 2010; Jenkins et al., 1998). In this study we use the well-characterised activated $h\beta_c$ mutant,
29
30 FIA, and a second-site mutant with a tyrosine to phenylalanine substitution at position 577
31
32 (Y577F) that selectively abolishes granulocyte differentiation and enhances macrophage
33
34 differentiation (Brown et al., 2004). This has provided a model system in which to dissect
35
36 GM differentiation induced through the GM-CSF receptor. The Tyrosine 577 residue of $h\beta_c$
37
38 has been previously shown to be a key signaling residue associated with binding of the Shc
39
40 adapter molecule and is part of a small phosphorylation-dependent motif, which regulates
41
42 alternative survival and proliferation pathways (Okuda et al., 1997; Powell et al., 2009;
43
44 Guthridge et al., 2006; Ramshaw et al., 2007). Here we focus on defining downstream events,
45
46 associated with the Tyr577 residue, and on linking these to the lineage-fate choice between
47
48 granulocyte and macrophage differentiation. We show that the Y577F mutation is associated
49
50 with enhanced β -catenin protein accumulation and *Tcf4* gene expression and we demonstrate
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1 a central role for these factors in promoting macrophage differentiation at the expense of
2 granulocyte differentiation.
3

4 5 **Materials and Methods**

6 7 **Cell culture**

8
9 The culture conditions of FDB1 cells, the construction of FIA Δ and FIA Δ Y577F retroviral
10 expression plasmids, and the generation of stable cell lines have been previously described
11 (Brown et al., 2004). Before treatment of cells with inhibitors, cells were washed 3 times and
12 starved of growth factor for 16 hours in medium containing serum. Stimulation was carried
13 out for 5 minutes at 37°C by the use of 500 bone marrow units (BMU)/mL mouse (m)IL-3 or
14 mouse (m)GM-CSF. The GSK-3 Inhibitor IX , BIO, and control, MeBIO, (Merk Chemicals,
15 Nottingham, UK) were dissolved in DMSO and used at a final concentration of 2 μ M.
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30

31 **Microarray hybridisation and analysis**

32
33 FDB1 cells expressing either FIA Δ and FIA Δ Y577F were washed 3 times to remove growth
34 factor and a proportion of cells were harvested at time zero. Cells were then cultured without
35 factor for 72 hours for the second time point. Two biological replicates were prepared for
36 each cell line (supplemental Fig. 1). Comparisons were performed for each cell line over time
37 and direct comparisons between cell lines done at 0 and 72 hours. Additional dye swaps were
38 done with the FIA Δ / FIA Δ Y577F 0 hour direct comparison and the FIA Δ 0-72 hour comparison
39 (supplemental Fig. 2). RNA preparation and microarray analysis and hybridisation were
40 performed as described previously (Brown et al., 2006). Lineage specific gene lists were
41 defined as follows. Neutrophil associated genes were defined as genes with a significant
42 change over time in FIA Δ expressing cells ($p < 0.001$) but not FIA Δ Y577F cells. Macrophage
43 associated genes were defined as those with a significantly larger fold change over time in
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1 FIA Δ Y577F cells compared to FIA Δ cells ($p < 0.001$, supplemental Fig.2). We performed gene-
2 set enrichment analysis as previously described (Brown et al., 2006). Briefly, to test for
3 association of published TF target gene sets based on either differential expression (C/EBP)
4 (Gery et al., 2005) or CHIP (TCF and β -catenin) (Hatzis et al., 2008; Yochum et al., 2007)
5 with our data sets, we used the non-parametric Wilcoxon rank sum test as implemented in the
6 R statistical program (<http://www.r-project.org/>). We constructed our reference set of genes
7 based on ranking the FDR p-value for comparisons of reference-set and test-set. For the
8 C/EBP comparison we generated a reference set by ranking all of the genes on our array
9 using the FDR p-values for the change in expression over time in FIA Δ expressing cells and
10 examined the distribution of C/EBP target genes in our reference list. For the β -catenin and
11 TCF4 comparisons we generated a reference set by ranking all of the genes on our array
12 using FDR p-values for the change in expression over time in FIA Δ Y577F expressing cells and
13 examined the distribution of β -catenin and TCF4 target genes in our reference list. A
14 significant result from the Wilcoxon rank sum test indicated that the gene-set of interest
15 displays an association with the indicated reference-set. Unsupervised clustering and
16 heatmaps of data were generated with MeV (<http://www.tm4.org/mev/>). The raw microarray
17 data is available in the Gene Expression Omnibus (GSE25857).
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42

43 QRT-PCR

44 FDB1 cells expressing either FIA Δ and FIA Δ Y577F were washed 3 times to remove growth
45 factor and a proportion of cells were harvested at time zero. Cells were then cultured without
46 factor and cells harvested at 24 hours and 72 hours. Parental FDB1 cells were also cultured in
47 GM-CSF and harvested at 24, 72 and 120 hours. Two biological replicates of this experiment
48 were performed. RNA was prepared using Trizol reagent (Invitrogen, Carlsbad, CA, USA) as
49 per the manufacturers instructions. cDNA was prepared using the QuantiTect Reverse
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1 Transcription Kit (Qiagen, Valencia, CA, USA). The sequences of the oligonucleotides used
2 for PCR are listed in supplemental Table 1. Gene-specific PCR reactions were performed for
3
4 40 cycles using FastStart Taq (Roche diagnostics, Indianapolis, IN, USA) and recommended
5
6 conditions. SYBR green (Invitrogen, Carlsbad, CA, USA) was added to a final concentration
7
8 of 0.6x per reaction and PCR was performed on the Rotor-Gene 6000 and related software
9
10 used for data collection and to determine mean expression values relative to beta-actin
11
12 (Corbett Research, Version 5.0, Qiagen, Valencia, CA, USA). Amplification products were
13
14 analyzed by melt curve and sequenced to confirm specificity.
15
16
17
18
19
20

21 **Construction of retroviral expression plasmids and transduction of FDB1 cells**

22
23 Constructs for FLAG-tagged full length TCF4 and Δ N-TCF4 in pcDNA3.1/Zeo were
24
25 obtained from Hans Clever (van de et al., 2002). The cDNAs were amplified from the
26
27 constructs using the oligos indicated in supplemental Table 1. The products were digested
28
29 with SfiI and ligated into SfiI digested murine stem cell virus (MSCV)-internal ribosome
30
31 entry site (IRES)-green fluorescence protein (GFP) retroviral vector (modified to contain SfiI
32
33 sites in the MCS). The construct for stabilised β -catenin (pCS2MMBCS33A) was obtained
34
35 from Rolf Kemler (Rottbauer et al., 2002). The β -catenin cDNA contains 4 amino acid
36
37 substitution mutations (Ser33Ala, Ser37Ala, Thr41Ala and Ser45Ala). β -catenin was
38
39 amplified using the oligos indicated in supplemental materials and methods and cloned into
40
41 MSCV-IRES-GFP as described above.
42
43
44
45
46
47

48 Virus production and FDB1 transduction was performed as previously described (Perugini et
49
50 al., 2009). For the TCF constructs, cells expressing GFP were sorted using flow cytometry
51
52 and allowed to recover overnight before using in assays. For the β catS33A construct, cells
53
54 expressing GFP were sorted to generate a line with stable β catS33A expression. Cell sorting
55
56
57
58
59
60
61
62
63
64
65

1 was performed on Beckman-Coulter ALTRA (Beckman-Coulter, Brea, CA, USA) or Becton-
2 Dickinson ARIA cell sorters (Becton-Dickinson, Franklin Lakes, NJ, USA).
3
4
5
6

7 **Proliferation and differentiation assays**

8
9 Growth was assessed using either CellTiter 96 AQueous One Solution Cell Proliferation
10 Assay (Promega, Madison, WI, USA), or trypan blue exclusion. The proportion of viable
11 cells was determined by trypan blue exclusion. To assess differentiation, cyospin
12 preparations were made, and slides stained with May-Grünwald Giemsa. 200 cells were
13 scored microscopically for morphology. In addition, cell surface staining was performed
14 using a rat anti-mouse cfms-PE conjugate and isotype control, IgG2a-PE, from eBiosciences
15 (San Diego, CA, USA) and analyzed by flow cytometry using a FC500 or XL-MS analyser
16 (Beckman-Coulter, Brea, CA, USA).
17
18
19
20
21
22
23
24
25
26
27
28
29
30

31 **Western immunoblot analysis and antibodies**

32
33 Cells were lysed in modified RIPA lysis buffer, separated by sodium dodecyl sulfate (SDS)-
34 polyacrylamide gel electrophoresis, and transferred to nitrocellulose. Proteins of interest were
35 detected by use of the appropriate antibodies and SuperSignal West Pico, West Dura or West
36 Femto substrates (Pierce Biotechnology, Thermo Scientific, Rockford, IL, USA). Mouse
37 monoclonal anti- β -catenin was purchased from BD Biosciences (Becton-Dickinson, Franklin
38 Lakes, NJ, USA). Rabbit polyclonal p38MAP Kinase and rabbit monoclonal
39 GSK3 β antibody, were purchased from Cell Signaling Technology (Beverly, MA, USA).
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Online Supplemental Material

Supplemental Table 1 includes sequences for oligonucleotides used for PCR and cloning. Supplemental Table 2 includes full lists of genes differentially regulated in macrophage and granulocyte lineages by Y577. Supplemental Table 3 includes the full list of β -catenin/Tcf4 target genes differentially regulated by Y577. Supplemental Fig. 1 contains mutant h β c expression and differentiation information for the cells used in the microarray analysis. Supplemental Fig. 2 contains microarray experimental design and volcano plots of genes differentially regulated by Y577. Supplemental Fig. 3 shows the gene set enrichment plot for β -catenin/Tcf4 target genes in FIA-Y577F regulated genes.

Results

A single tyrosine residue in GMR is required for granulocyte differentiation: a model of GM-CSF-induced lineage specification.

When cultured in GM-CSF, FDB1 cells form granulocytes and macrophages in approximately equal proportions and this can be mimicked in the absence of growth factor by ectopic expression of the h β c FIA activated mutant (McCormack and Gonda, 2000). To characterise the signaling pathways and downstream genes supporting granulocyte and macrophage differentiation induced by GMR we performed comparative gene expression profiling of the differentiation response for FDB1 cells expressing the FIA mutant and its derivative FIA Δ Y577F, which supports differentiation predominantly to macrophages (Brown et al., 2004). Cultures of FDB1 cells expressing the parental FIA mutant or the Y577F derivative were cultured in the absence of growth factor for 72 hours and assessed for the expected morphological differentiation prior to RNA extraction (supplemental Fig. 1). Microarray hybridisation and processing was carried out on the Compugen Mouse Oligo Library (v2, 21,997 65mers comprising 21,587 unique genes) as previously described (Brown et al., 2006). The differential gene expression in each population was determined over this time period and gene expression changes associated with mutation of Tyr577 were determined by linear modelling (supplemental Fig. 2A) (Brown et al., 2006). Gene expression changes were defined as Tyr577-associated and involved in promoting granulocyte differentiation if the change in expression was selectively lost in cells responding to the FIA Δ Y577 mutant (supplemental Fig. 2B). Genes with a significantly greater change over time in FIA Δ Y577F compared to FIA (supplemental Fig. 2B) were defined as suppressed by Tyr577 signaling, and associated with promoting macrophage differentiation. Lists of differentially-expressed genes were generated using an FDR p-value of 0.001 and a fold change cut-off of

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1.4. Using this approach we identified 153 up-regulated and 83 down-regulated genes associated specifically with intact Tyr577 signaling and differentiation of the granulocyte lineage and 166 up-regulated and 55 down-regulated genes associated with enhanced differentiation of the macrophage lineage in the absence of Tyr577 signaling (supplemental Table 2). The top 25 up and down regulated genes associated specifically with the granulocyte and macrophage lineages are shown in Fig. 1A and C respectively.

Consistent with the loss of neutrophil differentiation associated with the Y577 second-site mutant we identified differential expression of many known neutrophil genes amongst the Tyr577-regulated genes. These included granule proteins such as *Ltf*, *Ngp*, *Mmp8*, *Itgb2l*, *Camp*, *Prtn3*, *Lcn2*, *Ceacam1*, *S100a8*. Many of these genes are also targets of the C/EBP family of transcription factors several members of which, including C/EBP α and C/EBP ϵ , are important regulators of this lineage. Indeed, using gene-set enrichment analysis we identified a significant association of these genes with the C/EBP target gene-set generated by Gery *et al* (Gery et al., 2005) (p=0.00023). Ingenuity pathway analysis (IPA) of the full neutrophil associated gene list identified significantly associated canonical pathways. These revealed a network of down-regulated genes involved in IL-4 signaling (and T and B cell differentiation and function) consistent with suppression of some alternative lineages, and up-regulation of genes associated with leukocyte function (Fig. 1B).

As predicted, the genes that show enhanced up-regulation over time in the presence of the Y577F mutation were strongly associated with macrophage differentiation. These included genes involved in macrophage function, such as proteins normally found in the lysosomal compartment of macrophages (e.g. *Ctss*, *Psap*, *Mmp12*, *Asahl*) or cell surface proteins involved in the innate immune response (e.g. *Clecsf12*, *Clecsf10*, *Trem2*, *Ccr2*, *Itgax*). Of

1 particular interest are known key regulators of macrophage differentiation such as CSF1
2 receptor and ligand, PKC δ and the transcription factors *Egr1*, *Fos* and *C/EBP β* all of which
3 displayed large increases in expression selectively in the Y577F mutant over the 72 hour time
4 course (Fig. 1C-D). IPA canonical pathway analysis identified pathways associated with
5 rheumatoid arthritis, a disease with known GM-CSF induced macrophage involvement
6 (Hamilton, 2008) (Fig. 1D). In addition, the macrophage associated gene list also contained
7 genes significantly associated with pathways of PPAR, IL-6, p38MAPK, GM-CSF and IL-3
8 signaling, that were not identified with the neutrophil associated gene list (Fig. 1B). Thus
9 gene expression analysis using this FDB1 differentiation model is consistent with signaling
10 from Tyr577 promoting a granulocyte differentiation program while suppressing key inducers
11 of macrophage differentiation.
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30

31 ***Tcf4* is a repressed target of Tyr577 signaling and a promoter of macrophage** 32 **differentiation**

33
34
35 Given that key regulators of macrophage differentiation are significantly up-regulated over
36 time in cells expressing the FI Δ Y577 mutant we next used this characteristic pattern to
37 identify additional potential regulators of macrophage differentiation. By microarray the
38 transcription factor *Tcf4* showed significantly enhanced up-regulation in cells expressing the
39 Y577F second-site mutant of FI Δ (FDR $p=1.8 \times 10^{-11}$, Fig. 1C). A comparison of the change in
40 expression for *Tcf4* and other macrophage lineage transcription factors (TFs) (*Egr1*, *Fos* and
41 *C/EBP β*) in FI Δ and FI Δ Y577F expressing cells was determined by quantitative RT-PCR (Q-
42 PCR) and is shown in Fig. 2A. The expression changes of *Tcf4*, *Egr1*, *Fos* and *Cebpb* were
43 consistent with the results obtained by microarray (Fig. 2A). Expression of these genes also
44 increases during GM-CSF-directed bi-lineage terminal differentiation of FDB1 cells (which
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1 proceeds more slowly than FIA-induced GM differentiation) over 120 hours (Fig. 2B). By
2 QPCR *Tcf4* mRNA expression increased from 1.8 fold at 72 hours in FIA cells to 7 fold in
3 FIA Δ Y577F cells and by 3.8 fold in GM-CSF-treated parental FDB1 cells at 72 hours (Fig. 2
4 A,B). This is consistent with *Tcf4* being a repressed target of the Y577 signaling pathway
5 with a potential role in promoting macrophage differentiation and/or suppressing granulocyte
6 differentiation. *Tcf4* is itself a target gene activated by the Tcf4/ β -catenin complex (Hatzis et
7 al., 2008) and up-regulation of *Tcf4* expression is likely to be an indication of Wnt pathway
8 activation. Further support for this was provided from IPA pathway analysis which identified
9 an association between the genes associated with Tyr577 signaling and the Wnt/ β -catenin
10 pathway, in particular up-regulation of *Tcf4*, as well as down-regulation of the Wnt
11 antagonist *Dkk1* (Fig. 1D).
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29

30 *Tcf4* is a DNA-binding cofactor of β -catenin and a role for *Tcf4* has not previously been
31 reported in promoting myeloid differentiation. To further investigate the possibility that β -
32 catenin/TCF4 is involved in promoting macrophage differentiation in FDB1 cells we
33 ectopically expressed full length *Tcf4* and *Tcf4* lacking the amino terminal β -catenin
34 interaction domain (Δ N-*Tcf4*; Fig. 2C) using the MSCV-IRES-GFP (MIG) vector (Fig. 2D-
35 F). FDB1 cells were transduced with MIG-*Tcf4*, MIG- Δ N-*Tcf4* or MIG vector control and
36 infected cells (GFP+) enriched by flow cytometry. After sorting, cells were seeded into
37 medium containing IL-3 (for growth) or GM-CSF (GM differentiation) and growth, viability
38 and differentiation were measured over a 5 day period. Expression of *Tcf4* resulted in
39 significantly reduced growth over 5 days in both IL-3 and GM-CSF (Fig. 2D) which was also
40 associated with significantly reduced viability (as measured by trypan blue exclusion) at day
41 5 in IL-3, but not GM-CSF (data not shown). Interestingly, while Δ N-*Tcf4* was also able to
42 affect the growth of cells in IL-3, there was no effect on cell expansion in response to GM-
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1 CSF (Fig. 2D) indicating that the latter effect is dependent on the β -catenin interaction
2 domain. The *Tcf4* and ΔN -*Tcf4* growth suppression in IL-3 was associated with a
3 significantly decreased number of blasts and an increase in the number of granulocytes,
4 although the majority of cells in IL-3 in all cases were still of undifferentiated morphology
5 (Fig. 2E). Importantly, under conditions of GM-CSF-induced differentiation, we found that
6 ectopic *Tcf4* expression significantly increased the number of cells differentiating to
7 macrophages, a response that was not associated with expression of the ΔN -*Tcf4* mutant (Fig.
8 2E). This enhanced macrophage differentiation was also associated with increased cell
9 surface expression of the macrophage marker, c-fms (Fig. 2F). These results show that *Tcf4*
10 has the capacity, most likely via an interaction with β -catenin, to promote differentiation of
11 the macrophage lineage.
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30

31 **GM-CSF receptor activation induces β -catenin stabilization that is negatively regulated** 32 **by the Tyr577 pathway** 33

34 We next determined the levels of β -catenin protein present in FDB1 cells expressing the FIA
35 mutant or the Y577F derivative, or responding to GM-CSF over 72 hours. In cells responding
36 to GM-CSF or expressing FIA we observed accumulation of β -catenin at 24 hours following
37 IL-3 withdrawal, which was absent at 72 hours (Fig. 3A). In contrast, in cells expressing
38 FIA Δ Y577F, which differentiate predominantly to macrophages, β -catenin was constitutively
39 present (Fig. 3A). This is consistent with mutation of Tyr577 disrupting a pathway that
40 normally regulates the stability of β -catenin. To further examine the pathway regulating β -
41 catenin stabilization we treated FDB1 cells with the Glycogen synthase kinase 3 β (GSK3 β)
42 inhibitor BIO. GSK3 β is a well-recognised negative regulator of β -catenin stability and one
43 of the characterised effects of inhibition of GSK3 β activity is constitutive β -catenin protein
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1 stabilisation (Liu et al., 2002; Holmes et al., 2008). Parental FDB1 cells were treated with 2
3 μ M BIO or the control N-methylated analogue (Me-BIO). As predicted, inhibition of GSK3 β
4 with BIO led to increased β -catenin protein levels measured at 16 hours (Fig. 3B). BIO
5 treatment did not significantly affect viability of the cells, as measured by trypan blue
6 exclusion (data not shown) but resulted in a significant suppression of growth in response to
7 both IL-3 and GM-CSF (Fig. 3C). In response to GM-CSF, there was a significant increase in
8 the number of macrophages with concomitant decreases in both blasts and granulocytes (Fig.
9 3D). This was also associated with a clear increase in the number of cells expressing c-fms
10 (Fig. 3E). We also observed increased levels of macrophages in response to IL-3 in the
11 presence of BIO although this increase was not significant.
12
13
14
15
16
17
18
19
20
21
22
23
24
25

26 **β -catenin stabilization is sufficient to specify macrophage differentiation in FDB1 cells**

27
28 We next tested the ability of β -catenin to directly mediate macrophage differentiation by
29 ectopically expressing a stabilized form of β -catenin. For this we used the MIG vector to
30 express an engineered version of β -catenin containing point mutations at the GSK3 β and
31 casein kinase phosphorylation sites (Ser33Ala, Ser37Ala, Thr41Ala, Ser45Ala) (Liu et al.,
32 2002; Rottbauer et al., 2002). Expression of this β -catenin mutant (herein referred to as
33 β catS33A) has previously been shown to render the β -catenin protein resistant to degradation
34 and consequently mimic a constitutive Wnt signal (Aoki et al., 2002; Rottbauer et al., 2002).
35 FDB1 cells were transduced with MIG- β catS33A or MIG vector control and infected cells
36 (GFP+) enriched by flow cytometry. After sorting, cells were seeded into medium containing
37 IL-3 or GM-CSF and growth, viability and differentiation were measured over a 5 day period.
38
39 Western immunoblot analysis at day 5 confirmed the increase of β -catenin protein in cells
40 transduced with MIG- β catS33A, in both IL-3 and GM-CSF (Fig 4A). Over-expression of
41 β catS33A did not affect growth of FDB1 cells in IL-3, however in the presence of GM-CSF
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1 we observed significantly enhanced growth of the MIG- β catS33A FDB1 cell population (Fig.
2 4B). There was no difference in the viability of the cell populations (as measured by trypan
3 blue exclusion) over the 5 day period (data not shown). Importantly, after 5 days in GM-CSF,
4
5 differentiation of the MIG- β catS33A cell population was associated with a significantly
6
7 increased proportion of macrophages ($p=0.027$) compared to vector-control cells (Fig. 4C-D).
8
9 While having a significant effect on differentiation in GM-CSF, β catS33A was not sufficient
10
11 to induce differentiation to macrophages in the presence of IL-3 (Fig. 4C-D). Taken together
12
13 with the BIO-induction of differentiation this demonstrates that, in the context of GM-CSF
14
15 signaling, stabilization of β -catenin promotes specification of macrophage differentiation in
16
17 this FDB1 model system.
18
19
20
21
22
23
24
25
26
27

28 **Tcf4/ β -catenin target genes are enriched in Tyr577-regulated genes**

29 To further investigate the link between Tyr577 signaling, Tcf4/ β -catenin activity and
30
31 macrophage differentiation we investigated whether other known β -catenin/Tcf4 target genes,
32
33 are regulated in response to Tyr577 signaling. For this we used gene-set enrichment analysis
34
35 to compare the full set of Y577-differentially regulated genes with a combined gene-set of
36
37 direct TCF4 and β -catenin target genes (347 genes) derived from two chromatin
38
39 immunoprecipitation (ChIP) studies in colorectal cancer cell lines (Hatzis et al., 2008;
40
41 Yochum et al., 2007). This analysis identified a significant association between the 347 β -
42
43 catenin/Tcf4 target genes and the genes significantly differentially regulated over time by
44
45 FI Δ Y577F ($p=1.7 \times 10^{-11}$, Wilcoxon rank-sum test, supplemental Fig. 3). The full list of
46
47 significantly differentially expressed β -catenin/TCF4 targets (113 genes) is shown in
48
49 supplemental Table 2. This analysis showed a clear association of the Tyr577-regulated genes
50
51 with β -catenin and Tcf4 direct target genes. *Egr1* is the β -catenin/Tcf4 direct-target gene with
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1 the largest-fold differential expression in FIΔY577F expressing cells over time suggesting a
2 key macrophage promoting role for this lineage-specific TF downstream of the Tyr577
3 signaling pathway. Differential regulation of *Egr1* in the FIΔY577F mutant was also
4 validated by QPCR (Fig. 2A). As shown in Fig. 5 *Egr1*, although not specified by IPA as a
5 Wnt/β-catenin signaling-related gene, an identified ChIP target of the β-catenin/TCF4
6 complex (Yochum et al., 2007) and is independently connected to multiple β-catenin/Tcf4
7 targets, consistent with a model of macrophage differentiation that involves Wnt/β-catenin
8 modulation of *Egr1* activity (Fig. 6).
9

20 Discussion

21 While genetic and functional studies provide clear evidence for the importance of GM-CSF
22 signaling in macrophage differentiation, the pathways that contribute to this process are still
23 incompletely defined. Here we define a novel signaling pathway from the GM-CSF receptor
24 that we propose contributes to the lineage fate of bi-potential GM progenitors. The key
25 intracellular Tyr577 residue in the common β subunit of the GM-CSF receptor has been
26 shown previously to be a determinant of the extent of granulocyte and macrophage
27 differentiation in the FDB1 cell line model (Brown et al., 2004). An *in vivo* mutant model of
28 Tyr577 signaling also showed expansion of progenitor cells in response to GM-CSF
29 consistent with a defect in GM progenitor differentiation (Ramshaw et al., 2007). Our
30 analysis comparing gene expression in the activated (FIΔ) mutant of GMR, that mediates
31 factor-independent macrophage and granulocyte differentiation, with that of the second-site
32 mutant FIΔY577F, is consistent with the observed reduction in morphological granulocyte
33 differentiation upon mutation of Tyr577 (Brown et al., 2004). Here we focused on *Tcf4* which
34 displayed similar expression to other regulators of macrophage differentiation in the FDB1
35 system (Fig. 2). *Tcf4* is a member of the Tcf/Lef family that combines with β-catenin to form
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1 transcriptional complexes that regulate target gene transcription. The Tyr577 mutation results
2 in increased *Tcf4* expression and is associated with reduced granulocyte differentiation and
3 enhanced differentiation to the macrophage lineage. Our data are most consistent with *Tcf4*
4 functioning as a promoter of differentiation and tumour suppressor in the GM lineage. Forced
5 expression of *Tcf4* in FDB1 cells responding to GM-CSF demonstrated a functional role in
6 promoting macrophage differentiation. This effect was dependent on the β -catenin interaction
7 domain, consistent with the known interaction and cooperation between Tcf4 and β -catenin.
8
9

10
11
12
13
14
15
16
17
18
19
20 Activation of *Tcf4* transcription downstream of GMR is most likely a result of β -catenin
21 accumulation as *Tcf4* is itself a target gene of the Tcf4/ β -catenin transcriptional complex
22 (Hatzis et al., 2008). We found that β -catenin accumulated in the presence of the FIDY577F
23 mutant. We also observed transient accumulation of β -catenin at the 24 hour timepoint
24 following GM-CSF stimulation of FDB1 cells (Fig. 3A) and expression of a stabilised β -
25 catenin or inhibition of GSK3 β with pharmacological inhibitors mimicked *Tcf4* over-
26 expression and increased the number of cells differentiating to macrophages. Thus three
27 independent approaches demonstrate that β -catenin/Tcf4 activity promotes macrophage
28 differentiation in the FDB1 system. The ability of BIO to stabilize β -catenin downstream of
29 GM-CSF signalling suggests that, as in other systems, GSK3 β is key to regulating β -catenin
30 protein levels and therefore activation of this pathway in response to GM-CSF. Modification
31 of GSK3 β signalling by the GMR has not been previously investigated and although not
32 directly shown here, the accumulation β -catenin in cells expressing the FIDY577F mutant
33 suggests that this residue may normally have a role in regulating GSK3 β activity in response
34 to GM-CSF. Previous studies have linked Tyr577 to binding of Shc and activation and
35 regulation of Gab2, Akt/PI3K and SHIP related pathways (Gu et al., 2000; Dijkers et al.,
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1999; Ramshaw et al., 2007). Interestingly, mutation of this residue in different contexts has been associated with both reduced and enhanced activation of Akt (Dijkers et al., 1999; Ramshaw et al., 2007). Preliminary analysis of signalling from F1Δ and F1ΔY577F in FDB1 cells suggests alterations in activation of both Akt and p38MAPK (data not shown) both of which are known regulators of the GSK3β/β-catenin axis (Liu et al., 2002; Cross et al., 1995; Thornton et al., 2008; Bikkavilli et al., 2008). Further mapping of this pathway downstream of the GM-CSF receptor in this cell line model will reveal the signalling events important for macrophage differentiation and modulation of β-catenin activity, and shed light on the interplay between growth factor receptor signalling and transcriptional regulation in myeloid differentiation.

While a role for β-catenin in stem cell function and progenitor commitment has been reported previously (Zhao et al., 2007), our observation of a differentiation-promoting and lineage modulation capacity represents a novel function for Tcf4/β-catenin in the hematopoietic system. Activation of β-catenin in response to M-CSF signaling supports the growth and survival of macrophages, consistent with our findings, although lineage specification was not examined in this context (Otero et al., 2009). Interestingly we also note that conditional activation of β-catenin in the hematopoietic system acts to reduce the number of GM progenitors, and colonies formed in response to GM-CSF overall, and blocks granulocyte colony formation completely, while maintaining permissive conditions for some macrophage colony formation (Scheller et al., 2006). These data support our hypothesis that β-catenin may have independent roles at different stages of haemopoiesis, including a role in committed progenitors for determining macrophage versus granulocyte differentiation decisions. To shed light on the possible mechanism of β-catenin/Tcf4 mediated macrophage differentiation we analysed the Tyr577-regulated genes and showed a significant enrichment

1 of β -catenin/TCF4 target genes. Of particular note was the known transcriptional mediator of
2 macrophage differentiation, *Egr1* which displayed an 8-fold increase in expression over 72
3 hours during FIΔY577F-induced macrophage differentiation and was the most significant
4 differentially regulated macrophage-associated gene. In primary myeloid progenitors *Egr1* is
5 controlled by the macrophage master regulator *PU.1* and induction of *Egr1* promotes the
6 transcription of macrophage genes, while repressing the alternative granulocyte lineage
7 associated genes (Laslo et al., 2006). This provides a likely mechanism by which β -
8 catenin/Tcf4 could influence macrophage differentiation. Recent reports have shown that
9 *Egr1* directly regulates *Tcf4* in endometrial carcinoma cells and link *Egr1* expression to
10 progression of colorectal cancer, a process which also involves β -catenin/Tcf4 (Saegusa et
11 al., 2008; Ernst et al.), suggesting the possibility of a positive feedback loop. Interestingly
12 like *β -catenin*, *Egr1* is also important for hematopoietic stem cell homeostasis (Min et al.,
13 2008; Zhao et al., 2007) suggesting that this regulatory loop may operate with different
14 outputs at the level of the HSC and the committed myeloid progenitor. Further dissection of
15 these roles will require stage or lineage specific deletion approaches to separate stem cell
16 effects from those important for later cell fate decisions and will shed light on their role in
17 GM lineage choice.

Acknowledgements.

The authors would like to acknowledge the Adelaide Microarray Centre for their technical assistance with the microarray and Mrs Silvia Nobbs, Mr Sandy McIntyre and Ms Kate Pilkington for assistance with flow cytometry. This work was supported by the U.S. National Institutes of Health, National Health and Medical Research Council of Australia and the Cancer Council of South Australia. A.L.B was a fellow of the Cancer Council of South Australia.

Author Contributions

A.L.B. and R.J.D. wrote the manuscript. A.L.B designed the experiments, performed the experiments and analyzed the data; D.G.S., T.S. and M.P. performed experiments and analysed the data; C.W. and C.H.K. analysed microarray data; S.S. and T.S. provided technical assistance and advice; I.L. and T.J.G were involved in data interpretation and critical review of the manuscript.

Conflicts of Interest

The authors declare no competing financial interests.

References

- 1
2
3
4 Aoki, M., Sobek, V., Maslyar, D.J., Hecht, A., and Vogt, P.K., 2002. Oncogenic
5 transformation by beta-catenin: deletion analysis and characterization of selected
6 target genes. *Oncogene* 21, 6983-6991.
7
- 8 Bikkavilli, R.K., Feigin, M.E., and Malbon, C.C., 2008. p38 mitogen-activated protein kinase
9 regulates canonical Wnt-beta-catenin signaling by inactivation of GSK3beta. *J. Cell*
10 *Sci.* 121, 3598-3607.
11
- 12 Brown, A.L., Peters, M., D'Andrea, R.J., and Gonda, T.J., 2004. Constitutive mutants of the
13 GM-CSF receptor reveal multiple pathways leading to myeloid cell survival,
14 proliferation, and granulocyte-macrophage differentiation. *Blood* 103, 507-516.
15
- 16 Brown, A.L., Wilkinson, C.R., Waterman, S.R., Kok, C.H., Salerno, D.G., Diakiw, S.M.,
17 Reynolds, B., Scott, H.S., Tsykin, A., Glonek, G.F., Goodall, G.J., Solomon, P.J.,
18 Gonda, T.J., and D'Andrea, R.J., 2006. Genetic regulators of myelopoiesis and
19 leukemic signaling identified by gene profiling and linear modeling. *J.Leukoc.Biol.*
20 80, 433-447.
21
- 22 Conti, L., and Gessani, S., 2008. GM-CSF in the generation of dendritic cells from human
23 blood monocyte precursors: recent advances. *Immunobiology* 213, 859-870.
24
- 25 Cross, D.A., Alessi, D.R., Cohen, P., Andjelkovich, M., and Hemmings, B.A., 1995.
26 Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B.
27 *Nature* 378, 785-789.
28
- 29 D'Andrea, R.J., Harrison-Findik, D., Butcher, C.M., Finnie, J., Blumbergs, P., Bartley, P.,
30 McCormack, M., Jones, K., Rowland, R., Gonda, T.J., and Vadas, M.A., 1998.
31 Dysregulated hematopoiesis and a progressive neurological disorder induced by
32 expression of an activated form of the human common beta chain in transgenic mice.
33 *J.Clin.Invest* 102, 1951-1960.
34
- 35 Dijkers, P.F., van Dijk, T.B., de Groot, R.P., Raaijmakers, J.A., Lammers, J.W.,
36 Koenderman, L., and Coffey, P.J., 1999. Regulation and function of protein kinase B
37 and MAP kinase activation by the IL-5/GM-CSF/IL-3 receptor. *Oncogene* 18, 3334-
38 3342.
39
- 40 Dranoff, G., Crawford, A.D., Sadelain, M., Ream, B., Rashid, A., Bronson, R.T., Dickersin,
41 G.R., Bachurski, C.J., Mark, E.L., and Whitsett, J.A., 1994. Involvement of
42 granulocyte-macrophage colony-stimulating factor in pulmonary homeostasis.
43 *Science* 264, 713-716.
44
- 45 Enzler, T., Gillessen, S., Manis, J.P., Ferguson, D., Fleming, J., Alt, F.W., Mihm, M., and
46 Dranoff, G., 2003. Deficiencies of GM-CSF and interferon gamma link inflammation
47 and cancer. *J. Exp. Med.* 197, 1213-1219.
48
- 49 Ernst, A., Aigner, M., Nakata, S., Engel, F., Schlotter, M., Kloor, M., Brand, K., Schmitt, S.,
50 Steinert, G., Rahbari, N., Koch, M., Radlwimmer, B., Weitz, J., and Lichter, P., 2011.
51 A gene signature distinguishing CD133hi from CD133- colorectal cancer cells:
52 essential role for EGR1 and downstream factors. *Pathology (Phila)*. 43, 220-227.
53
54
55
56
57
58
59
60
61
62
63
64
65

- 1 Gery, S., Gombart, A.F., Yi, W.S., Koeffler, C., Hofmann, W.K., and Koeffler, H.P., 2005.
2 Transcription profiling of C/EBP targets identifies Per2 as a gene implicated in
3 myeloid leukemia. *Blood* 106, 2827-2836.
- 4 Gu, H., Maeda, H., Moon, J.J., Lord, J.D., Yoakim, M., Nelson, B.H., and Neel, B.G., 2000.
5 New role for Shc in activation of the phosphatidylinositol 3-kinase/Akt pathway. *Mol.*
6 *Cell. Biol.* 20, 7109-7120.
- 7
8
9 Guthridge, M.A., Powell, J.A., Barry, E.F., Stomski, F.C., McClure, B.J., Ramshaw, H.,
10 Felquer, F.A., Dottore, M., Thomas, D.T., To, B., Begley, C.G., and Lopez, A.F.,
11 2006. Growth factor pleiotropy is controlled by a receptor Tyr/Ser motif that acts as a
12 binary switch. *EMBO J.* 25, 479-489.
- 13
14
15 Hamilton, J.A., 2008. Colony-stimulating factors in inflammation and autoimmunity. *Nat*
16 *Rev Immunol* 8, 533-544.
- 17
18
19 Hansen, G., Hercus, T.R., McClure, B.J., Stomski, F.C., Dottore, M., Powell, J., Ramshaw,
20 H., Woodcock, J.M., Xu, Y., Guthridge, M., McKinstry, W.J., Lopez, A.F., and
21 Parker, M.W., 2008. The structure of the GM-CSF receptor complex reveals a distinct
22 mode of cytokine receptor activation. *Cell* 134, 496-507.
- 23
24
25 Hatzis, P., van der Flier, L.G., van Driel, M.A., Guryev, V., Nielsen, F., Denissov, S.,
26 Nijman, I.J., Koster, J., Santo, E.E., Welboren, W., Versteeg, R., Cuppen, E., van de
27 Wetering, M., Clevers, H., and Stunnenberg, H.G., 2008. Genome-wide pattern of
28 TCF7L2/TCF4 chromatin occupancy in colorectal cancer cells. *Mol. Cell. Biol.* 28,
29 2732-2744.
- 30
31
32 Holmes, T., O'Brien, T.A., Knight, R., Lindeman, R., Symonds, G., and Dolnikov, A., 2008.
33 The role of glycogen synthase kinase-3beta in normal haematopoiesis, angiogenesis
34 and leukaemia. *Curr. Med. Chem.* 15, 1493-1499.
- 35
36
37 Jenkins, B.J., Blake, T.J., and Gonda, T.J., 1998. Saturation mutagenesis of the beta subunit
38 of the human granulocyte-macrophage colony-stimulating factor receptor shows
39 clustering of constitutive mutations, activation of ERK MAP kinase and STAT
40 pathways, and differential beta subunit tyrosine phosphorylation. *Blood* 92, 1989-
41 2002.
- 42
43
44 Jenkins, B.J., D'Andrea, R., and Gonda, T.J., 1995. Activating point mutations in the
45 common beta subunit of the human GM-CSF, IL-3 and IL-5 receptors suggest the
46 involvement of beta subunit dimerization and cell type-specific molecules in
47 signalling. *EMBO J.* 14, 4276-4287.
- 48
49
50 Kondo, M., Scherer, D.C., Miyamoto, T., King, A.G., Akashi, K., Sugamura, K., and
51 Weissman, I.L., 2000. Cell-fate conversion of lymphoid-committed progenitors by
52 instructive actions of cytokines. *Nature* 407, 383-386.
- 53
54
55 Laslo, P., Spooner, C.J., Warmflash, A., Lancki, D.W., Lee, H.J., Sciammas, R., Gantner,
56 B.N., Dinner, A.R., and Singh, H., 2006. Multilineage transcriptional priming and
57 determination of alternate hematopoietic cell fates. *Cell* 126, 755-766.
- 58
59
60
61
62
63
64
65

- 1 Liu, C., Li, Y., Semenov, M., Han, C., Baeg, G.H., Tan, Y., Zhang, Z., Lin, X., and He, X.,
2 2002. Control of beta-catenin phosphorylation/degradation by a dual-kinase
3 mechanism. *Cell* 108, 837-847.
- 4 Lopez, A.F., Hercus, T.R., Ekert, P., Littler, D.R., Guthridge, M., Thomas, D., Ramshaw,
5 H.S., Stomski, F., Perugini, M., D'Andrea, R., Grimbaldston, M., and Parker, M.W.,
6 2010. Molecular basis of cytokine receptor activation. *IUBMB Life* 62, 509-518.
- 7
8
9
10 Martinez-Moczygemba, M., Doan, M.L., Elidemir, O., Fan, L.L., Cheung, S.W., Lei, J.T.,
11 Moore, J.P., Tavana, G., Lewis, L.R., Zhu, Y., Muzny, D.M., Gibbs, R.A., and
12 Huston, D.P., 2008. Pulmonary alveolar proteinosis caused by deletion of the GM-
13 CSFRalpha gene in the X chromosome pseudoautosomal region 1. *J. Exp. Med.* 205,
14 2711-2716.
- 15
16 McClure, B.J., Hercus, T.R., Cambareri, B.A., Woodcock, J.M., Bagley, C.J., Howlett, G.J.,
17 and Lopez, A.F., 2003. Molecular assembly of the ternary granulocyte-macrophage
18 colony- stimulating factor receptor complex. *Blood* 101, 1308-1315.
- 19
20
21 McClure, B.J., Woodcock, J.M., Harrison-Findik, D., Lopez, A.F., and D'Andrea, R.J., 2001.
22 GM-CSF binding to its receptor induces oligomerisation of the common beta-subunit.
23 *Cytokine* 13, 240-243.
- 24
25
26 McCormack, M.P., and Gonda, T.J., 1999. Myeloproliferative disorder and leukaemia
27 induced in mice by different classes of constitutive mutants of the human IL-3/IL-
28 5/GM-CSF receptor common beta subunit. *Oncogene* 18, 7190-7199.
- 29
30
31 McCormack, M.P., and Gonda, T.J., 2000. Novel murine myeloid cell lines which exhibit a
32 differentiation switch in response to IL-3 or GM-CSF, or to different constitutively
33 active mutants of the GM-CSF receptor beta subunit. *Blood* 95, 120-127.
- 34
35
36 Metcalf, D., Begley, C.G., Williamson, D.J., Nice, E.C., De Lamarter, J., Mermod, J.J.,
37 Thatcher, D., and Schmidt, A., 1987. Hemopoietic responses in mice injected with
38 purified recombinant murine GM-CSF. *Exp.Hematol.* 15, 1-10.
- 39
40
41 Min, I.M., Pietramaggiore, G., Kim, F.S., Passegue, E., Stevenson, K.E., and Wagers, A.J.,
42 2008. The transcription factor EGR1 controls both the proliferation and localization of
43 hematopoietic stem cells. *Cell Stem Cell* 2, 380-391.
- 44
45
46 Miyajima, A., Mui, A.L., Ogorochi, T., and Sakamaki, K., 1993. Receptors for granulocyte-
47 macrophage colony-stimulating factor, interleukin-3, and interleukin-5. *Blood* 82,
48 1960-1974.
- 49
50
51 Nishinakamura, R., Nakayama, N., Hirabayashi, Y., Inoue, T., Aud, D., McNeil, T., Azuma,
52 S., Yoshida, S., Toyoda, Y., Arai, K., and et al., 1995. Mice deficient for the IL-
53 3/GM-CSF/IL-5 beta c receptor exhibit lung pathology and impaired immune
54 response, while beta IL3 receptor-deficient mice are normal. *Immunity* 2, 211-222.
- 55
56
57 Okuda, K., Smith, L., Griffin, J.D., and Foster, R., 1997. Signaling functions of the tyrosine
58 residues in the beta chain of the granulocyte-macrophage colony-stimulating factor
59 receptor. *Blood* 90, 4759-4766.
- 60
61
62
63
64
65

- 1 Otero, K., Turnbull, I.R., Poliani, P.L., Vermi, W., Cerutti, E., Aoshi, T., Tassi, I., Takai, T.,
2 Stanley, S.L., Miller, M., Shaw, A.S., and Colonna, M., 2009. Macrophage colony-
3 stimulating factor induces the proliferation and survival of macrophages via a
4 pathway involving DAP12 and beta-catenin. *Nat Immunol* 10, 734-743.
- 5
6 Paine, R., III, Preston, A.M., Wilcoxon, S., Jin, H., Siu, B.B., Morris, S.B., Reed, J.A., Ross,
7 G., Whitsett, J.A., and Beck, J.M., 2000. Granulocyte-macrophage colony-stimulating
8 factor in the innate immune response to *Pneumocystis carinii* pneumonia in mice. *J.*
9 *Immunol.* 164, 2602-2609.
- 10
11 Perugini, M., Brown, A.L., Salerno, D.G., Booker, G.W., Stojkoski, C., Hercus, T.R., Lopez,
12 A.F., Hibbs, M.L., Gonda, T.J., and D'Andrea, R.J., Alternative modes of GM-CSF
13 receptor activation revealed using activated mutants of the common beta-subunit.
14 *Blood* 115, 3346-3353.
- 15
16
17 Perugini, M., Kok, C.H., Brown, A.L., Wilkinson, C.R., Salerno, D.G., Young, S.M., Diakiw,
18 S.M., Lewis, I.D., Gonda, T.J., and D'Andrea, R.J., 2009. Repression of Gadd45alpha
19 by activated FLT3 and GM-CSF receptor mutants contributes to growth, survival and
20 blocked differentiation. *Leukemia*.
- 21
22
23 Powell, J.A., Thomas, D., Barry, E.F., Kok, C.H., McClure, B.J., Tsykin, A., To, L.B.,
24 Brown, A., Lewis, I.D., Herbert, K., Goodall, G.J., Speed, T.P., Asou, N., Jacob, B.,
25 Osato, M., Haylock, D.N., Nilsson, S.K., D'Andrea, R.J., Lopez, A.F., and Guthridge,
26 M.A., 2009. Expression profiling of a hemopoietic cell survival transcriptome
27 implicates osteopontin as a functional prognostic factor in AML. *Blood* 114, 4859-
28 4870.
- 29
30
31
32 Ramshaw, H.S., Guthridge, M.A., Stomski, F.C., Barry, E.F., Ooms, L., Mitchell, C.A.,
33 Begley, C.G., and Lopez, A.F., 2007. The Shc-binding site of the betac subunit of the
34 GM-CSF/IL-3/IL-5 receptors is a negative regulator of hematopoiesis. *Blood* 110,
35 3582-3590.
- 36
37
38 Rottbauer, W., Saurin, A.J., Lickert, H., Shen, X., Burns, C.G., Wo, Z.G., Kemler, R.,
39 Kingston, R., Wu, C., and Fishman, M., 2002. Reptin and pontin antagonistically
40 regulate heart growth in zebrafish embryos. *Cell* 111, 661-672.
- 41
42
43 Saegusa, M., Hashimura, M., Kuwata, T., Hamano, M., Watanabe, J., Kawaguchi, M., and
44 Okayasu, I., 2008. Transcription factor Egr1 acts as an upstream regulator of beta-
45 catenin signalling through up-regulation of TCF4 and p300 expression during trans-
46 differentiation of endometrial carcinoma cells. *J. Pathol.* 216, 521-532.
- 47
48
49 Scheller, M., Huelsken, J., Rosenbauer, F., Taketo, M.M., Birchmeier, W., Tenen, D.G., and
50 Leutz, A., 2006. Hematopoietic stem cell and multilineage defects generated by
51 constitutive beta-catenin activation. *Nat Immunol* 7, 1037-1047.
- 52
53
54 Smith, A., Metcalf, D., and Nicola, N.A., 1997. Cytoplasmic domains of the common α -chain
55 of the GM-CSF/IL-3/IL-5 receptors that are required for inducing differentiation or
56 clonal suppression in myeloid leukaemic cell lines. *EMBO J.* 16, 451-464.
- 57
58 Suzuki, T., Sakagami, T., Rubin, B.K., Noguee, L.M., Wood, R.E., Zimmerman, S.L.,
59 Smolarek, T., Dishop, M.K., Wert, S.E., Whitsett, J.A., Grabowski, G., Carey, B.C.,
60
61
62
63
64
65

1 Stevens, C., van der Loo, J.C., and Trapnell, B.C., 2008. Familial pulmonary alveolar
2 proteinosis caused by mutations in CSF2RA. *J. Exp. Med.* 205, 2703-2710.

3 Thornton, T.M., Pedraza-Alva, G., Deng, B., Wood, C.D., Aronshtam, A., Clements, J.L.,
4 Sabio, G., Davis, R.J., Matthews, D.E., Doble, B., and Rincon, M., 2008.
5 Phosphorylation by p38 MAPK as an alternative pathway for GSK3beta inactivation.
6 *Science* 320, 667-670.
7

8
9 van de, W.M., Sancho, E., Verweij, C., de Lau, W., Oving, I., Hurlstone, A., van der, H.K.,
10 Battle, E., Coudreuse, D., Haramis, A.P., Tjon-Pon-Fong, M., Moerer, P., van den,
11 B.M., Soete, G., Pals, S., Eilers, M., Medema, R., and Clevers, H., 2002. The beta-
12 catenin/TCF-4 complex imposes a crypt progenitor phenotype on colorectal cancer
13 cells. *Cell.* 111, 241-250.
14
15

16 Yochum, G.S., McWeeney, S., Rajaraman, V., Cleland, R., Peters, S., and Goodman, R.H.,
17 2007. Serial analysis of chromatin occupancy identifies beta-catenin target genes in
18 colorectal carcinoma cells. *Proc. Natl. Acad. Sci. U. S. A.* 104, 3324-3329.
19
20

21 Zhao, C., Blum, J., Chen, A., Kwon, H.Y., Jung, S.H., Cook, J.M., Lagoo, A., and Reya, T.,
22 2007. Loss of beta-catenin impairs the renewal of normal and CML stem cells in vivo.
23 *Cancer Cell* 12, 528-541.
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Figure Legends

Fig. 1. Y577 regulated genes

A. Heatmap showing the expression of the top 25 up and down regulated genes associated with FIA induced factor independent granulocyte differentiation over 72 hours (see materials and methods for details of gene-set derivations). **B.** IPA defined canonical pathways significantly associated with the neutrophil gene set Lysine= lysine degradation, LES= leukocyte extravasation signaling, CES= caveolar-mediated endocytosis signaling. **C.** Heatmap showing the expression of the top 25 up and down regulated genes associated with FIA-Y577F induced factor independent macrophage differentiation over 72 hours. **D.** IPA defined canonical pathways associated with the macrophage gene set, AP= acute phase response signaling, RA= rheumatoid arthritis. The M value (log₂ fold change) for both FIA or FIA-Y577F expressing cells was converted to a colour scale with red indicating that gene expression increases between 0 and 72 hours and green indicating that the gene expression decreases with the colour intensity indicating the magnitude of regulation (range log₂, -3 to +3). Black boxes indicate individual genes involved in the indicated pathway. Tcf7l2=Tcf4.

Fig. 2. *Tcf4* is regulated by GM-CSF and promotes macrophage differentiation

Quantitative real-time PCR was used to determine the expression of the indicated genes. Expression was normalised to β -actin and expression is shown relative to 0 hours. Results shown are the average of two experiments **A.** FDB1 cells expressing FIA and FIA-Y577F were cultured without factor and RNA extracted at 0, 24 and 72 hours. **B.** Parental FDB1 cells were culture in GM-CSF and RNA extracted at 0, 24, 72 and 120 hours. **C.** Full length TCF4 and the engineered form lacking the N-terminal β -catenin interaction domain are depicted. The β -catenin interaction domain is indicated by a black box and the DNA binding domain is indicated by a grey box. **D.** FDB1 parental cells were transduced with a MSCV-IRES-GFP

1 retrovirus encoding TCF4, Δ N-TCF4 or a control retrovirus and selected for GFP expression
2 by FACS. Cells were washed and placed in the indicated growth conditions. Expansion of
3 GFP positive cells was determined by assessing viable cell number using trypan blue
4 exclusion and flow cytometry to determine the proportion of GFP positive cells at the
5 indicated time points. **E.** At day 5, cells were cytocentrifuged, Wright-Giemsa stained and
6
7 200 cells for each condition were scored microscopically for morphology. **F.** At day 5 cells
8 were stained with PE-conjugated anti-c-fms and the percentage of c-fms positive cells in the
9 GFP positive population was determined for each cell line. A representative flow histogram is
10 shown. Error bars represent SEM (n=4) and *=p<0.05, **=<0.01, ***=p<0.001 (unpaired,
11 two sided t-test).
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26

27 **Fig. 3. β -catenin stabilization is associated with increased macrophage differentiation**

28
29 **A.** FDB1 cells expressing FIA and FIA Δ Y577F were cultured without factor and parental cells
30 in GM-CSF and cell lysates were made at 0, 24 and 72 hours. Lysates were western blotted
31 with the indicated antibodies. Representative photo-micrographs were taken at the 72 hour
32 timepoint for FDB1 FIA and FIA Δ Y577F cells and at 120 hours for parental cells in GM-CSF.
33
34
35
36
37
38 **B.** FDB1 cells growing in response to IL-3 or undergoing GM differentiation in response to
39 GM-CSF were incubated with 2 μ M of the GSK3 β inhibitor BIO ((2'Z,3'E)-6-
40 Bromindirubin-3'-oxime) or N-methylated control analogue (Me-BIO). Activity of BIO at
41 16 hours was assessed by detection of β -catenin protein by western analysis. **C.** Cell growth
42 was determined at days 2 and 5 of GSK3 β inhibition by trypan blue exclusion. **D.** At day 5
43 cells were cytocentrifuged, Wright-Giemsa stained and 200 cells for each condition were
44 scored microscopically for morphology. **E.** At day 5 cells were stained with PE-conjugated
45 anti-c-fms and the percentage of c-fms positive cells was determined for each cell population.
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1 Error bars represent SEM (n=3) and *=p<0.05, **=<0.01, ***=p<0.001 (unpaired, two sided
2 t-test).
3
4
5
6

7 **Fig. 4. β -catenin directs macrophage differentiation in response to GM-CSF receptor**
8 **signaling**
9

10 FDB1 cells were transduced with MIG encoding β -catenin with mutations S33A, S37A,
11 T41A, S45A (β catS33A) or vector alone. **A.** GFP positive cells were placed in IL-3 or GM-
12 CSF and after 5 days were assessed for expression of stabilised β -catenin by western
13 analysis. **B.** Growth was assessed over 4 days using AQueous one solution proliferation
14 assay. **C.** At day 5 cells were cytocentrifuged, Wright-Giemsa stained and 200 cells for each
15 condition were scored by morphology. Error bars represent SEM (n=2) and *=p<0.05
16 (unpaired, two sided t-test). **D.** Photomicrographs of cells at day 5.
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31

32 **Fig. 5. A TCF4/ β -catenin target gene network in FI Δ Y577F regulated genes**
33

34 **A.** The overlapping TCF4/ β -catenin and macrophage genes with an FDR p<0.05 (113) were
35 subjected to Ingenuity Pathway Analysis (IPA). The genes were subject to IPA mapping of
36 network interactions and filtered for direct interactions and networks containing genes
37 identified as involved in Wnt/ β -catenin signaling. The colour indicates the direction of
38 differential expression in our macrophage regulated gene list with red indicating that gene
39 expression increases between 0 and 72 hours and green indicating that the gene expression
40 decreases with the colour intensity indicating the magnitude of regulation. CTNNB1= β -
41 catenin.
42
43
44
45
46
47
48
49
50
51
52
53


54 **Fig. 6. Novel molecular interactions in monopoiesis regulated by GM-CSF signaling**
55

56 Signaling emanating from Tyr577 of the GMR leads to stabilisation of the β -catenin protein
57
58
59
60
61
62
63
64
65


(possibly though GSK3 β inactivation) which, in combination with Tcf4, leads to differentiation of the macrophage lineage at the expense of neutrophil lineage.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65


A



B



C



D




Fig 2

Fig. 2






Fig. 3


A




B



C



D



E






Fig. 4


A



B



C



D




Fig 5

Fig. 5






Fig. 6





supplemental material

[Click here to download e-component: brown et al supplemental material.doc](#)

supplemental figures

[Click here to download e-component: supplemental figures.ppt](#)